Risk Factors and Response to Therapy in Heart and Lung Transplant Patients with Posttransplant Lymphoproliferative Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12613001094763

Acronym

Nil

Enrollment

Registered

2013-09-30

Start date

2012-08-01

Completion date

2013-08-12

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This paper reports on the post-transplant lymphoproliferative disease (PTLD) experience of a single centre heart and lung transplant unit from its inception in 1984 to 2011 with respect to patient demographics, risk factors, management and outcomes. This detailed retrospective analysis aims to identify risk factors and describe outcomes in heart and lung transplant patients with PTLD to understand the unique clinical features of their disease in order to further develop tailored treatment strategies and prophylaxis.

Interventions

Observational study looking at factors which contribute to the risk of developing Post-transplant Lymphoproliferative Disease (PTLD) in heart and lung transplant patients as well as looking at what treatment was recieved and how this correlates to outcomes. Participants will be observed in a retrospective fashion from the time of diagnosis of PTLD until present

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Heart and Lung transplant patients who were transplanted at St Vincent's Hospital, Sydney from the commencement of the transplant program until 2013. Posttransplant lymphoproliferative disease was an inclusion criteria. No other malignant diseases were elligible.

Exclusion criteria

Nil

Outcome results